Guardian Point Capital’s Acumen Pharmaceuticals ABOS Stock Holding History

Guardian Point Capital’s Portfolio ABOS Stock Details ABOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-130,000	Closed	-$528K	–	7
2023 Q1	$528K	Sell	130,000 -170,000	-57%	-$888K	0.44%	7
2022 Q4	$1.62M	Sell	300,000 -100,000	-25%	-$672K	1.28%	7
2022 Q3	$4.01M	Sell	400,000 -100,000	-20%	-$574K	2.93%	6
2022 Q2	$2.35M	Hold	500,000	–	–	1.29%	11
2022 Q1	$1.96M	Hold	500,000	–	–	0.71%	13
2021 Q4	$3.38M	Hold	500,000	–	–	0.78%	16
2021 Q3	$7.43M	Buy	+500,000	New	+$8.32M	1.72%	15

Other funds holding ABOS

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

KIA

Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Guardian Point Capital's ABOS Position: Q2 2023 in Review

Guardian Point Capital sold out of Acumen Pharmaceuticals (ABOS) in Q2 2023, closing a stake of 130,000 shares — an estimated $528K sold.

Guardian Point Capital first reported a position in ABOS in Q3 2021 and held it in 7 quarters. The position peaked at $7.43M in Q3 2021. 53 funds tracked by Wall St. Rank hold ABOS as of Q2 2023.

Guardian Point Capital reported no remaining Acumen Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Guardian Point Capital sold 130,000 Acumen Pharmaceuticals shares in Q2 2023, an estimated $528K.
Guardian Point Capital first reported a position in Acumen Pharmaceuticals in Q3 2021 and held it in 7 quarters.
Guardian Point Capital's Acumen Pharmaceuticals position peaked at $7.43M in Q3 2021.
53 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2023.

Based on Guardian Point Capital's 13F filing for Q2 2023, filed 14 Aug 2023.